Prilosec OTC Heats Up Heartburn Sector; Competitors Set Sights On Launch
This article was originally published in The Tan Sheet
Executive Summary
Pfizer has initiated a competitive advertising campaign against Prilosec as Procter & Gamble gears up to introduce the OTC version of the proton pump inhibitor this quarter
You may also be interested in...
Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes
Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry
Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes
Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry
Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes
Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry